Management of RSV infections in adult recipients of hematopoietic stem cell transplantation

Shah, Jharna N.; Chemaly, Roy F.

doi:10.1182/blood-2010-08-263400

Cited by 229 publications

(274 citation statements)

References 68 publications

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…3 The frequency of RSV infection in adults is about 2-17% among HSCT recipients. 6,9,10 This incidence is lower than that observed in the present study conducted in infants. Severity is highest in HSCT patients.…”

Section: Discussioncontrasting

confidence: 55%

“…or oral applications, but no controlled clinical trials to reach treatment consensus have been conducted. 6,13 Aerosolized ribavirin has been the most frequently used treatment for RSV after HSCT. 10 Its use has been limited on account of the lack of proven efficacy and potential toxicity to caregivers exposed to the drug, including potential teratogenicity.…”

Section: Discussionmentioning

confidence: 99%

“…9,14,16 In our study, no related side effects were observed, which was consistent with previous studies reporting on the use of ribavirin in the hepatitis C infection setting. 17 Recently, Shah et al 6 reviewed and summarized the use of ribavirin from 26 available studies involving adult HSCT patients infected with RSV. The authors concluded that patients receiving antiviral treatment had better outcomes than untreated patients.…”

Section: Intravenous Ribavirin In Pediatric Hematopoietic Transplantamentioning

confidence: 99%

“…Aerosolized ribavirin has been the most widely used formulation, especially among adult HSCT patients. 6 Currently, it is the only approved therapy for RSV infection among high-risk infants and young children. Contrary to the available information regarding aerosolized formulations of ribavirin, there is a paucity of published studies using i.v.…”

Section: Introductionmentioning

confidence: 99%

“…That is why no consensus concerning the most effective approach has been achieved. 6 Ribavirin is available in aerosol, i.v. and oral formulations.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Molinos-Quintana

Soto

Gómez-Rosa

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

A Molinos-Quintana, C Pé rez-de Soto, M Gó mez-Rosa, JA Pé rez-Simó n and JM Pé rez-HurtadoRespiratory syncytial virus (RSV) is a potential cause of serious morbidity and even mortality among children undergoing hematopoietic SCT (HSCT). Contrary to the available information regarding the aerosolized formulation of ribavirin, there is a paucity of published studies using i.v. ribavirin in adults, and very few single reports on pediatric patients. Aerosolized drug administration has been limited by potential toxicity and special air-flow requirements. In this regard, i.v. ribavirin could prevent these disadvantages, but its efficacy and safety remain controversial in the pediatric HSCT setting. The present study describes the outcome of six pediatric patients undergoing HSCT with nine episodes of proven RSV. Four episodes corresponded to lower respiratory tract infection (LRTI) and five presented with upper respiratory tract infection (URTI). All LRTI patients showed favorable clinical responses, with 100% survival and no progression to LRTI in the remaining five URTI. No side effects were documented during ribavirin administration. We conclude that ribavirin was well tolerated intravenously, without associated side effects, and was effective in the treatment of RSV in this limited number of pediatric HSCT patients. The role and efficacy of i.v. ribavirin needs to be further clarified by prospective controlled trials in pediatric populations.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Intravenous Ribavirin In Pediatric Hematopoietic Transplantamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…That is why no consensus concerning the most effective approach has been achieved. 6 Ribavirin is available in aerosol, i.v. and oral formulations.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations